ReviewBoneKEy reports2013
Clinical utility of serum sclerostin measurements.
Review in BoneKEy reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Clinical Data for Parametrization ofFrontiers in bioengineering and biotechnology · 2022Pooled it
- Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Trial
- Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans.The Journal of clinical endocrinology and metabolism · 2017Trial
- Trial
- The Association of Bone-related Biomarkers With Incident Hip Fracture: A Nested Case-control Study.Journal of the Endocrine Society · 2025Article
- Association of heel bone mineral density with incident dementia among ageing adults: a population-based study from the UK Biobank.Aging clinical and experimental research · 2025Article
- Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus.Journal of clinical & translational endocrinology · 2025Article
- An In-Depth Analysis of Variable Dynamics Influencing Bone Mineral Density in Transfusion-Dependent Thalassemia Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer's disease progression.Nature metabolism · 2024Article
- Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.Frontiers in endocrinology · 2024Article
- ALK1 Signaling in Human Cardiac Progenitor Cells Promotes a Pro-angiogenic Secretome.Journal of cellular signaling · 2024Article
- Serum sclerostin levels as a diagnostic marker for osteoporosis.Bioinformation · 2024Article
- Current and Emerging Markers and Tools Used in the Diagnosis and Management of Chronic Kidney Disease-Mineral and Bone Disorder in Non-Dialysis Adult Patients.Journal of clinical medicine · 2023Review
- Endocrine Functions of Sclerostin.Current opinion in endocrine and metabolic research · 2023Article
- Mechanism of regulating macrophages/osteoclasts in attenuating wear particle-induced aseptic osteolysis.Frontiers in immunology · 2023Review
- Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis.Frontiers in physiology · 2023Review
- Article
- Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.Nature communications · 2022Article
- Sclerostin in Excessive Drinkers: Relationships with Liver Function and Body Composition.Nutrients · 2022Article
- Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia.Endocrinology and metabolism (Seoul, Korea) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway requisite for osteoblast development and activity. Efforts over the past several years have focused on unraveling the role of sclerostin in both normal physiological and pathological conditions. Sclerostin levels are undetectable in the serum of patients with sclerosteosis. In normal individuals, serum sclerostin levels are higher in males and increase in both sexes across the adult lifespan. Some, but not other, studies have demonstrated that higher serum sclerostin levels are associated with increased fracture risk, particularly when paired with lower bone mineral density. Levels of circulating sclerostin are highly correlated with bone marrow sclerostin levels. Sclerostin levels are inversely related to parathyroid hormone levels. Clinical conditions in which serum sclerostin levels have been measured include ankylosing spondylitis, chronic kidney disease, diabetes, fractures, hypercortisolism, multiple myeloma and spinal cord injury. Even within clearly defined clinical conditions, however, consistent changes in serum sclerostin levels have not always been seen. This may reflect differences in currently available commercial assays or sample sources (serum versus plasma), and suggests further study is needed before sclerostin measurements are introduced into routine clinical practice. Until such issues are resolved, measurement of sclerostin levels appears to be most useful for understanding the mechanisms by which osteocytes regulate bone turnover through the integration of hormonal, physical and pharmacological stimuli, rather than to guide clinical-care decisions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.